Memantine vs Pembrolizumab
Memantine vs Pembrolizumab: Overview
This comparison examines the pharmacological differences between Memantine and Pembrolizumab.
Mechanism of Action
Memantine: Non-competitive NMDA receptor antagonist.
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Pharmacokinetics
Half-life: Memantine β 60-80 hours; Pembrolizumab β 26 days.
Chemical Properties
Molecular Formula: Memantine β C12H21N.
Molecular Weight: Memantine β 179.3080 g/mol.
Type: Memantine β Small molecule; Pembrolizumab β Antibody.